Jaime Alberto Restrepo

TL;DR: The 9vHPV vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 in a susceptible population and generated an antibody response to HPV -6, 11, 16, and 18 that was noninferior to that generated by the qHPV Vaccine.

TL;DR: When administered to adolescents, the HPV4 vaccine demonstrated durability in clinically effective protection and sustained antibody titers over 8 years.

TL;DR: A randomized, international, double-blind, phase 2b-3 study of the 9-valent virus-like particle vaccine against human papillomavirus (HPV) in women 16 to 26 years of age was conducted in this article.

TL;DR: Concomitant administration of 9vHPV vaccine with MCV4/Tdap was generally well tolerated and did not interfere with the antibody response to any of these vaccines.

TL;DR: A 3-dose regimen of the 4vHPV vaccine was immunogenic, clinically effective, and generally well tolerated in preadolescents and adolescents during 10 years of follow-up, which support efforts to vaccinate this population against HPV before exposure.